aap Implantate AG
aap Implantate AG develops, manufactures, and markets traumatology products for orthopedics in Germany and internationally. The company offers LOQTEQ, an anatomical plating system for the treatment of ankle, straight plates, knee, elbow, wrist, and shoulder. It also provides hole screws and Repro Bone materials. The company sells its products directly to hospitals, purchasing groups, and hospital… Read more
aap Implantate AG (AAQ1) - Net Assets
Latest net assets as of June 2025: €9.38 Million EUR
Based on the latest financial reports, aap Implantate AG (AAQ1) has net assets worth €9.38 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€13.98 Million) and total liabilities (€4.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €9.38 Million |
| % of Total Assets | 67.09% |
| Annual Growth Rate | -18.69% |
| 5-Year Change | 1.65% |
| 10-Year Change | N/A |
| Growth Volatility | 27.7 |
aap Implantate AG - Net Assets Trend (2016–2024)
This chart illustrates how aap Implantate AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for aap Implantate AG (2016–2024)
The table below shows the annual net assets of aap Implantate AG from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €10.46 Million | +29.14% |
| 2023-12-31 | €8.10 Million | -36.84% |
| 2022-12-31 | €12.83 Million | +0.40% |
| 2021-12-31 | €12.78 Million | +24.14% |
| 2020-12-31 | €10.29 Million | -45.46% |
| 2019-12-31 | €18.87 Million | -45.96% |
| 2018-12-31 | €34.92 Million | -17.95% |
| 2017-12-31 | €42.56 Million | -22.30% |
| 2016-12-31 | €54.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to aap Implantate AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 623.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €41.83 Million | 399.84% |
| Total Equity | €10.46 Million | 100.00% |
aap Implantate AG Competitors by Market Cap
The table below lists competitors of aap Implantate AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PCC Exol SA
WAR:PCX
|
$9.65 Million |
|
SLP Resources Bhd
KLSE:7248
|
$9.66 Million |
|
Live Ventures Inc
NASDAQ:LIVE
|
$9.66 Million |
|
Pinnacle Silver and Gold Corp.
V:PINN
|
$9.66 Million |
|
Yw Company Limited
KQ:051390
|
$9.65 Million |
|
Avonmore Capital & Management Services Limited
NSE:AVONMORE
|
$9.64 Million |
|
Eureka Design Public Company Limited
BK:UREKA
|
$9.64 Million |
|
Airthings ASA
PINK:ARTGF
|
$9.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in aap Implantate AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,101,000 to 10,462,000, a change of 2,361,000 (29.1%).
- Net loss of 3,630,000 reduced equity.
- New share issuances of 3,215,000 increased equity.
- Other factors increased equity by 2,776,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.63 Million | -34.7% |
| Share Issuances | €3.21 Million | +30.73% |
| Other Changes | €2.78 Million | +26.53% |
| Total Change | €- | 29.14% |
Book Value vs Market Value Analysis
This analysis compares aap Implantate AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.09x to 1.76x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €14.58 | €1.36 | x |
| 2018-12-31 | €11.94 | €1.36 | x |
| 2019-12-31 | €5.88 | €1.36 | x |
| 2020-12-31 | €0.32 | €1.36 | x |
| 2021-12-31 | €2.57 | €1.36 | x |
| 2022-12-31 | €1.95 | €1.36 | x |
| 2023-12-31 | €0.90 | €1.36 | x |
| 2024-12-31 | €0.77 | €1.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently aap Implantate AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.75%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.51x
- Recent ROE (-34.70%) is above the historical average (-42.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 26.71% | 139.51% | 0.16x | 1.17x | €9.15 Million |
| 2017 | -21.78% | -85.04% | 0.22x | 1.19x | €-13.53 Million |
| 2018 | -21.95% | -71.11% | 0.26x | 1.21x | €-11.16 Million |
| 2019 | -103.02% | -165.59% | 0.45x | 1.39x | €-21.33 Million |
| 2020 | -85.44% | -94.28% | 0.47x | 1.91x | €-9.82 Million |
| 2021 | -21.13% | -22.18% | 0.53x | 1.80x | €-3.98 Million |
| 2022 | -19.99% | -22.26% | 0.57x | 1.58x | €-3.85 Million |
| 2023 | -98.30% | -69.38% | 0.66x | 2.13x | €-8.77 Million |
| 2024 | -34.70% | -29.75% | 0.77x | 1.51x | €-4.68 Million |
Industry Comparison
This section compares aap Implantate AG's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $275,054,215
- Average return on equity (ROE) among peers: -85.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| aap Implantate AG (AAQ1) | €9.38 Million | 26.71% | 0.49x | $9.65 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |